Although approximately half of the administered dose of irinotecan is recovered in urine, scarce data are available on the association of renal function with irinotecan pharmacokinetics and toxicity. Here, these relationships are investigated in 187 patients treated with irinotecan in a three-weekly schedule. No significant effects on irinotecan pharmacokinetics were found in these patients. However, in 131 patients treated with the registered dose, categorized renal function was related to hematological toxicity. The incidence of grade 3-4 neutropenia decreased as function of creatinine clearance, particularly in nonsmoking patients (P < 0.01). Patients with slower creatinine clearance (35-66 ml/min) had a four-times higher risk of grade 3-4 neutropenia (58% vs. 14%; P < 0.001). This study suggests that pretreatment renal function values are associated with irinotecan-induced neutropenia. A confirmatory analysis is warranted to determine whether measures of renal function should be incorporated in future attempts toward individualized treatment with irinotecan.

Additional Metadata
Persistent URL dx.doi.org/10.1038/sj.clpt.6100513, hdl.handle.net/1765/32384
Citation
de Jonge, M.J.A, van der Bol, J.M, Mathijssen, A.H.J, van Gelder, T, Wiemer, E.A.C, Sparreboom, A, & Verweij, J. (2008). Renal function as a predictor of irinotecan-induced neutropenia. Clinical Pharmacology and Therapeutics, 84(2), 254–262. doi:10.1038/sj.clpt.6100513